Research · Sep 3, 2026
[MIR] Mirion Technologies Thesis 2026: A Radiation-Detection Pure-Play Rides the Nuclear-Power Renaissance and Cancer-Therapy Demand
Mirion Technologies (NYSE: MIR), headquartered in Atlanta, Georgia (with substantial-scale operations across San Ramon CA + Pittsburgh + Smyrna GA + France + UK + Germany + Switzerland + Belgium + Canada), is a global radiation-detection + measurement + monitoring company producing radiation-monitoring + measurement + dosimetry + analysis instruments for nuclear-power + medical + defense + research + industrial customers globally. The company has a multi-decade lineage combining Mirion Technologies (founded 2005 by merger of Synodys + Global Dosimetry Solutions + others) + Canberra Industries acquisition 2016 (the multi-decade nuclear-power radiation-monitoring leader) + Sun Nuclear acquisition 2022 (medical-radiation-therapy-and-dosimetry leader) + other bolt-ons. October 2021 Mirion went public via SPAC merger with GS Acquisition Holdings Corp II (Goldman Sachs-sponsored SPAC) with Charterhouse Capital Partners private-equity sponsor exit. Under President & CEO Thomas Logan (CEO since 2024, prior CFO + interim CEO of Mirion + longtime Mirion senior leadership), FY2025 closes with selected various aggregate revenue ~$0.85-0.90B (~8-12% YoY growth), adjusted EBITDA ~$0.18-0.22B (~21-24% margins), adjusted EPS ~$0.40-0.55, net leverage ~3.0-3.8x (selectively-elevated post-SPAC + selective-M&A), and ~226M shares outstanding. The first deep-dive — Industrial segment + nuclear-power-renaissance + defense-detection franchise — covers Industrial (~$0.55-0.65B, ~65-70%, dominant pillar). Nuclear power plant radiation-monitoring + instrumentation is the dominant sub-segment with ~50%+ global market share: area-radiation-monitors + process-and-effluent-monitoring + personnel-dosimetry + emergency-preparedness instrumentation supplied to Westinghouse Electric Company (dominant US-PWR nuclear reactor OEM), EDF (Électricité de France, dominant French + EU nuclear operator), KEPCO Hydro & Nuclear Power (Korean), Rosatom (Russian), Mitsubishi Heavy Industries, Hitachi, Toshiba, AECL/Canadian Nuclear Laboratories, Bruce Power + Ontario Power Generation, EPRI, IAEA + national regulators. Military + defense radiation-detection covers hand-held + portable + vehicle-mounted detection for US DoD + UK MoD + allied military + Department of Homeland Security + Customs and Border Protection radiation-detection-portals + first-responder + emergency-management agencies. Government + research-lab instruments serve DOE national-labs (Los Alamos, Oak Ridge, Lawrence Livermore, Argonne, Pacific Northwest, Brookhaven, Sandia), CERN, KEK, ORNL, ITER. The nuclear-power-renaissance structural-tailwind: 2024-2030 global-nuclear-power-industry experiencing largest-multi-decade pipeline-expansion across Small Modular Reactors (SMRs) commercializing — NuScale Power (SMR), X-energy, BWXT, TerraPower (Bill Gates), Holtec, Rolls-Royce SMR (RR-LN), Westinghouse AP-300, GE-Hitachi BWRX-300, Kairos Power, Oklo (OKLO), Last Energy; Grid-scale nuclear new-builds across US (Vogtle 3/4, Diablo Canyon-extension), France (EPR2), UK (Hinkley Point C + Sizewell C), Korea (APR1400s), Japan, China, India, Eastern Europe (Poland, Czech Republic, Romania, Bulgaria, Hungary); Existing-reactor life-extensions across US (~20-year-license-renewal cycle for US-PWR-and-BWR-fleet), France, Canada, Korea; AI-data-center-power-demand-driven nuclear-power-build with Big Tech-and-hyperscaler-driven nuclear demand (Microsoft + Constellation CEG Three Mile Island re-start 2024, Amazon + Talen TLN Susquehanna nuclear-PPA, Google + Kairos Power SMR-PPA + other Big-Tech-nuclear-deal pipeline). Competes with Thermo Fisher Scientific (TMO ~$170-200B dominant scientific-instrument at much-larger scale), Eckert & Ziegler (EUZ-DE), Tracerco (Johnson Matthey), Ludlum, Berthold (German), Polimaster; in defense with Smiths Detection (SMIN-LN), Bertin Technologies (French), L3Harris (LHX); in medical-radiation-therapy QA with Sun Nuclear (Mirion subsidiary), IBA Dosimetry (Belgian), Standard Imaging, Varian/Siemens Healthineers (SIEGY). The second deep-dive — Medical segment + radiation-therapy + cancer-care + multi-decade compounder thesis — covers Medical (~$0.25-0.30B, ~30-35%, higher-growth + selectively-recurring) providing radiation-therapy dosimetry (Sun Nuclear 2022 acquisition brought dominant medical-radiation-therapy-QA franchise serving customers using Varian SIEGY + Elekta EKTA-B-SE + Accuray ARAY), nuclear-medicine instrumentation (PET + SPECT + radiopharmacy), medical-physics equipment (QA + calibration + patient-safety for cancer-treatment + diagnostic-imaging), and personnel-dosimetry services (selectively-recurring-revenue dosimeter-badge + radiation-exposure-tracking subscription for hospital-staff + nuclear-power-workers + research-staff). Multi-decade compounder thesis combines Industrial nuclear-power-renaissance structural-tailwind, Medical radiation-therapy + cancer-care durability, dominant ~50%+ global market share + IP + regulatory-certification moat, disciplined capital-allocation under Thomas Logan post-SPAC integration, selective M&A (Sun Nuclear 2022), operating-leverage on post-SPAC operational-efficiency-improvements, and deleveraging-pace. Capital position is moderately-leveraged, deleveraging-focused, no-dividend, post-SPAC-execution: net debt ~$0.55-0.75B providing ~3.0-3.8x leverage (target ~2.5-3.0x by FY2027 via EBITDA growth + FCF debt-paydown), B+/BB- speculative-grade, ~$0.08-0.15B cash + undrawn revolver liquidity, FCF ~$70-110M/yr selectively-pressured by interest-expense + capex + post-SPAC integration-costs, no regular dividend, minimal buybacks pending deleveraging, ~226M shares broadly stable. At ~$13-18 per share, equity value ~$2.9-4.1B, EV ~$3.5-4.9B, ~25-40x EPS and ~17-25x EV/EBITDA — premium radiation-detection-pure-play reflecting nuclear-renaissance + medical-therapy + ~50%+ share. Base case: revenue grows ~10-13% + EBITDA-margin ~22-25% + EPS $0.50-0.65 + leverage moderates to ~2.8-3.3x + ~12-25% return. Bull case: nuclear-renaissance accelerates + SMR + AI-data-center + EPS $0.65-0.85 + re-rate 30-40x + 30-50%+ return. Bear case: nuclear-build-pace-disappoints + EPS $0.35-0.45 + de-rate 18-22x + flat-to-negative.